September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Assessing the utility of phenylephrine 2.5% for diagnostic pupillary dilation
Author Affiliations & Notes
  • James C Liu
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States
    Indiana University School of Medicine Transitional Residency Program, Indianapolis, Indiana, United States
  • Wesley Green
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States
  • Susan M Culican
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States
  • Gregory Van Stavern
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States
  • Footnotes
    Commercial Relationships   James Liu, None; Wesley Green, None; Susan Culican, None; Gregory Van Stavern, None
  • Footnotes
    Support  This work was supported by awards to the Department of Ophthalmology and Visual Sciences at Washington University from a Research to Prevent Blindness, Inc. unrestricted grant, the NIH Vision Core Grant P30 EY 0268, and awards from the Lacy Glaucoma Research Fund to SMC.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5538. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      James C Liu, Wesley Green, Susan M Culican, Gregory Van Stavern; Assessing the utility of phenylephrine 2.5% for diagnostic pupillary dilation. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5538.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Phenylephrine eye drops are routinely used in dilated eye examinations, but have increased drastically in price over the past few years. We performed a prospective, unmasked, crossover pilot study to evaluate whether the addition of phenylephrine to tropicamide produces any statistically and clinically significant change in pupil size.

Methods : Twenty healthy students and faculty members affiliated with the Washington University School of Medicine were enrolled. Each had 3 distinct dilating eye drop regimens administered to the left eye on separate days. The routine regimen used clinically at Washington University for dilated eye examination is tropicamide (T) + proparacaine (PP) + phenylephrine (PE) (T+PP+PE). This was considered the standard therapy to which tropicamide + proparacaine (T+PP) and tropicamide alone (T alone) were compared. Measurements of pupil size were made before and 30 minutes after eye drop administration using an automated pupillometer. Primary outcome measures were post-dilation pupil size and proportion of pupils able to achieve post-dilation pupil size >7mm. The latter served as a measure of clinical significance. Comparisons between the 3 regimens were made using paired t-tests and McNemar’s test, with T+PP+PE serving as the standard therapy.

Results : Mean post-dilation pupil size was 7.94±0.78mm, 7.64±0.78mm, and 7.48±0.77mm for T+PP+PE, T+PP, and T alone, respectively. T+PP+PE was statistically superior to T+PP (p=0.0043) and T alone (p<0.0001) with respect to post-dilation pupil size. The proportion of pupils able to achieve adequate pupil dilation of >7mm was 90%, 80%, and 70% for T+PP+PE, T+PP, and T alone, respectively. No statistical difference was observed in each regimen’s ability to achieve adequate pupil dilation of >7mm (T+PP+PE and T+PP: p=0.47; T+PP+PE and T alone: p=0.13).

Conclusions : The addition of phenylephrine eye drops to tropicamide provides larger pupil dilation, but the magnitude of benefit is marginal and clinically insignificant in this healthy cohort.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×